Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28386195 | 0.98 | CHRM2 (0.59) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL28390369 | 0.89 | LMNA (0.58) | CHRM2SMN1; SMN2KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL29438821 | 0.87 | CHRM2 (0.70) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL230222 | 0.87 | CHRM2 (0.70) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL25211342 | 0.85 | CHRM2 (0.68) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL317984 | 0.85 | CHRM2 (0.68) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| Zinc Ion SCHEMBL30442739 | 0.85 | CHRM2 (0.68) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| Zinc Ion SCHEMBL30205248 | 0.85 | CHRM2 (0.68) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL18493706 | 0.85 | CHRM2 (0.68) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL434742 | 0.84 | CHRM2 (0.68) | CHRM2MAOAMAOBSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831640-A | Gas delivery device | 密歇根大学董事会 | 2020-02-21 | — | — | CN | claimed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | claimed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | disclosed |
| CN-119013244-A | Process for the hydrogenation of unsaturated esters | 庄信万丰股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12024549-B2 | Compound having affinity substance to soluble protein, cleavable portion and reactive group, or salt thereof | AJINOMOTO CO., INC. (JP) | 2024-07-02 | — | — | US | disclosed |
| CN-117624031-A | Preparation method of 4- (ethylaminomethyl) pyridine | 安徽华邦药业有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240010915-A1 | Etching Solution For Titanium Nitride And Molybdenum Conductive Metal Lines | VERSUM MATERIALS US, LLC (US) | 2024-01-11 | — | — | US | disclosed |
| CN-117362219-A | Preparation method of 4- (ethylaminomethyl) pyridine | 南京法恩化学有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117083259-A | Selective catalytic olefin isomerization for the manufacture of perfume ingredients or intermediates | 国际香精香料公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-114206948-B | catheter insertion device | 密歇根大学董事会 | 2023-11-03 | — | — | CN | disclosed |
| US-6093714-A | AN ANTIALLERGENS FOR TREATMENT AND PREVENTION OF BRONCHIAL ASTHMA, ECZEMA, HIVES, ALLERGIC GASTROINTESTINAL TROUBLES, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS | MEIJI SEIKA KAISHA, LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| WO-1999033800-A1 | INDOLE DERIVATIVES AS INHIBITORS OR FACTOR XA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-08 | — | — | WO | disclosed |
| US-5872257-A | CHELATING LIGANDS FOR FROMING COORDINATION COMPLEXES WITH METAL IN LIQUID AND SUPERCRITICAL CARBONDIOXIDE OF COVELENTLY BONDED GROUPS SELECTED FORM DITHIOCARBAMATE, PICOLYLAMINE, THIOL, A SPACERS AND FLUOROALKYLOXY OR FLUOROMETHYLENE | UNIVERSITY OF PITTSBURGH (US) | 1999-02-16 | — | — | US | disclosed |
| CN-1190971-A | Tricyclic benzazepine * compounds | MEIJI SEIKA CO (JP) | 1998-08-19 | — | — | CN | disclosed |
| EP-0834512-A1 | TRICYCLIC BENZAZEPINE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1998-04-08 | — | — | EP | disclosed |
| US-5354866-A | Treating HIV infections | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0366085-A2 | Tetrahydropyrimidines, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-05-02 | — | — | EP | disclosed |
| US-4097481-A | ANTIARRHYTHMIC AGENTS | RIKER LABORATORIES, INC. (US) | 1978-06-27 | — | — | US | disclosed |
| US-4006239-A | Benzoic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024549-B2 | Compound having affinity substance to soluble protein, cleavable portion and reactive group, or salt thereof | SPPL2B, CSTB, SPPL2A | CHRM2 3962/4885MAOA 1651/4885MAOB 1018/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | CHRM2 4110/4885MAOA 2508/4885MAOB 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.